The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney

About this episode

The episode discusses the critical intersection of biotech, patent law, and AI with insights from Dr. Kate Neville.

Recorded October 31, 2025 In this episode of BioTalk Unzipped , Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property. If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening. We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape. Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney. In This Episode We Discuss: • The difference between patent prosecution and patent litigation • Why it is never too early for biotech startups to think about IP • The U.S. one-year grace period vs. Europe’s stricter disclosure rules • What “Freedom to…

People in this episode

Hosts: Gregory Austin, Dr. Chad Briscoe

Guest: Dr. Kate Neville

Topics covered

• biotech
• patent law
• AI
• intellectual property
• commercial viability
• startup strategy

Keywords

• biotech
• patent prosecution
• intellectual property
• AI tools
• freedom to operate
• FDA-approved drugs
• commercialization

Mentioned in this episode

Organizations: Marshall, Gerstein & Borun

More episodes of BioTalk Unzipped

• The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi · June 11, 2026 · 30 min
• Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker · April 25, 2026 · 51 min
• Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains · March 19, 2026 · 1h 0m
• Long-acting Cell-Based Gene Therapy, Fabry Disease and Beyond with Glafabra CEO, Dr. Chris Hopkins · December 22, 2025 · 49 min
• Fail Fast, Learn Faster: Drug Development in Rare Disease with Dr. Binodh DeSilva · October 23, 2025 · 31 min
• Unlocking Antibody Development with AI with Dr. Pin-Kuang Lai · September 12, 2025 · 18 min